Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Milestone reached by Xoma in collaboration with Allergan

Dec. 27, 1999

Allergan expands ophthalmic allergy product portfolio

Dec. 21, 1999

Swiss regulatory authorities grant Visudyne Therapy its first approval

Dec. 20, 1999

Pharmos seeks approval for Loterox in the U.K.

Dec. 20, 1999

New to the U.K. market: ophthalmic steroid from Alcon causes less IOP elevation

Dec. 16, 1999

AEterna presents promising phase I data for AE-941 in AMD

Dec. 13, 1999

Cambridge NeuroScience and Allergan extend ophthalmic research collaboration

Dec. 9, 1999

Projected enrollment exceeded in Miravant's phase III AMD trials

Dec. 8, 1999

Ciba Vision licenses Destiny's photodynamic therapy technology

Dec. 6, 1999

FDA advisory panel recommends approval of Visudyne therapy for wet AMD

Nov. 18, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...